Skip to main content
. 2020 Apr 30;12(5):1123. doi: 10.3390/cancers12051123

Figure 5.

Figure 5

Low-dose targeting of TGF-β receptor 1 sensitizes chemoresistant MDA-MB-468. (A) Gene expression analysis of growth factor ligands and cell surface receptors in docetaxel/doxorubicin-adapted MDA-MB-468 (RES) cells as a ratio compared to matched sensitive MDA-MB-468 (SENS) cells. (B) Protein expression of TGF-β receptors (TGFBR1/2) and ligand (TGFB2) comparing matched MDA-MB-468-sensitive and -resistant cell lines. (C) TGF-β receptor 1 inhibitor SB525334 dose curves with the addition of doxorubicin, p-glycoprotein pump inhibitor (Pgpi), and the combination of doxorubicin (50 nM), docetaxel (0.5 nM), and Pgpi (1 µM). (D) The change in the sensitivity of the resistant cell line compared to sensitive cell line under the conditions in (C). All experiments were performed in triplicate and plotted as average +/- SEM.